Everolimus, which targets the mammalian target of rapamycin (mTOR) pathway, appears to be effective in treating T cell lymphoma by inhibiting malignant T cell proliferation74. This evidence concerns the gene MTOR and T-cell non-Hodgkin lymphoma.